ANI Pharmaceuticals, Inc.
ANIP
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.6B
$71.23
▼ -1.06%
P/E
15.16
Mkt Cap
$1.6B
52-Wk Range
$70.15–$99.50
52-Week Range
$70.15 - $99.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 25.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Specialized manufacturing capabilities in potent, controlled, and complex formulations with high regulatory barriers to entry
- Integrated CDMO business providing recurring revenue and manufacturing utilization
- Established distribution network through major pharmacy chains, wholesalers, and group purchasing organizations
- Focus on niche therapeutic categories (oncology, controlled substances) with limited generic competition and pricing power
- Vertical integration from development through manufacturing and commercialization
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Moderate growth ahead
Expansion of oncology product portfolio addressing growing cancer treatment demand
Value
Trading at 0.6x Large Cap Pharma peers — a discount despite the growth profile.
Momentum
Weak
-11.1% over 3m
Quality
Excellent
High-growth business (31% revenue growth, 65% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying ANIP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 7, 2026
Reported EPS of $2.21 vs $2.04 consensus (+8.3% surprise). Revenue of $266.0M vs $260.1M expected (+2.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+8.3%
Revenue trend · last 8Q
—
+45%
+43%
+53%
+54%
+30%
+20%
+26%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$148.3M
$190.6M
$197.1M
$211.4M
$227.8M
$247.1M
$237.5M
$266.0M
Margins · last 8Q
Gross
0.0%
Operating
15.2%
Profit
9.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Aug 10, 2026
vs Industry
How ANIP stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related